So far viraDX has gained basically F all in AU/EU markets....

So far viraDX has gained basically F all in AU/EU markets. FebriDX is all or nothing.

Not the case. ViraDX is a seasonal product and will increase and decrease relative to the weather - ie. Winter being the driver. More people being sick = more product being bought. The issue with the EU market is that routine use of POC testing in clinical practice has not been strongly adopted in these markets whereas it is standard practice in the US and as a result there is not reimbursement in place for POC tests which provides an additional economic barrier to their adoption in these markets - the US does.

The other thing people need to keep in mind is that the market needs to shift its focus from prescribing drugs as first point of call, to running these tests as a default practice. This could take time to achieve, however the market is moving towards a more antibiotic free mentality.

This is not a pump and dump. If it were, the sell off would have happened on Friday. Its up 33% month to date. It is recouping the losses from the CR which occurred earlier and other day trading is seeking value in the short term gains also. Don't be surprised if Monday comes along and there is a retrace without news. The bonus there is it would play into the technical analysis of cup and saucer which is still bullish.

They estimated $150,000 in sales within the first couple weeks of trade in the US. As i have pointed out also, there are more and more distributers/resellers coming on board and even another one found today.

News on major distributors will direct share price. Quarterly will provide guidance on revenue whether positive or negative. If people can see there is take up of the product, the price will move positively.